Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 3Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 10Lymphoid 10Plasma cell 5Myeloid 5Sarcoma 3Dermatologic 2CNS 2Gastrointestinal 1

Conditions

Oligodendroglioma 1Gliosarcoma 1Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 80Radiotherapy 41Bevacizumab 35Radiosurgery 23Magnetic Resonance Spectroscopy 20Cyclophosphamide 17Radiation 14Irinotecan 13Carboplatin 12Topotecan 11Nivolumab 11Lomustine 11Filgrastim 10Everolimus 10Etoposide 10Erlotinib Hydrochloride 10pembrolizumab 9Radiotherapy, Intensity-Modulated 9Ipilimumab 9Granulocyte Colony-Stimulating Factor 8Carmustine 8antineoplaston AS 2-1 7antineoplaston A10 7Surgical Procedures, Operative 7Mental Status and Dementia Tests 7Isotretinoin 7Granulocyte-Macrophage Colony-Stimulating Factor 7sargramostim 6Vincristine 6TPI-287 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × plerixafor × CNS × Clear all
NCT00669669 2022-05-18

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
12 enrolled 13 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT01339039 2017-11-17

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

Dana-Farber Cancer Institute

Phase 1 Terminated
26 enrolled
CNS

Astrocytoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡